Our Director of Marketing’s Grandfather died of a massive brain tumor when she was only about a year old. His last days were a combination of comatose and automatic speaking. He recited every line that he had ever spoken on stage (he was in the entertainment industry). Although she doesn’t remember it, it was very traumatic for her family.
Recurrent Glioblastoma Multiforme is the most common type of malignant primary brain tumor in adults. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation and chemotherapy. Additionally, Brain stem cell cancer is the most lethal cancer in children, with a survival rate of less than one year after diagnosis.
NeoPharm’s agreement with NINDS will serve as another step in pursuing the validation of the company’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (“IL-13”) and its impact on possibly increasing and enhancing the life span of patients diagnosed with terminal brain cancers.
Dr. Aquilur Rahman, Chief Scientific Advisor commented, “In conjunction with our confirmatory Phase III trial for IL-13, the studies at NINDS with imaging agents should provide further support and better targeting by optimizing delivery systems.” This is one more step to bringing hope to families touched by untreatable brain diseases.
Let us hear your thoughts below:
